1. COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study
- Author
-
Maria Guarino, Valentina Cossiga, Ilaria Loperto, Ilaria Esposito, Rosanna Ortolani, Andrea Fiorentino, Giuseppina Pontillo, Lucia De Coppi, Valentina Cozza, Alfonso Galeota Lanza, Giovanni Giuseppe Di Costanzo, Francesco Paolo Picciotto, Filomena Morisco, Guarino, Maria, Cossiga, Valentina, Loperto, Ilaria, Esposito, Ilaria, Ortolani, Rosanna, Fiorentino, Andrea, Pontillo, Giuseppina, De Coppi, Lucia, Cozza, Valentina, Galeota Lanza, Alfonso, Di Costanzo, Giovanni Giuseppe, Picciotto, Francesco Paolo, and Morisco, Filomena
- Subjects
Adult ,Hospitalization ,Male ,Multidisciplinary ,SARS-CoV-2 ,Incidence ,COVID-19 ,Humans ,Female ,Prospective Studies ,Middle Aged ,Liver Transplantation - Abstract
Liver transplant (LT) recipients are vulnerable to SARS-CoV-2-infection (COVID-19), due to immunosuppression and comorbidities. This study aimed to evaluate the impact of COVID-19 on LT recipients compared to general population in the Campania region. In this prospective double-centre study, we enrolled all consecutive adult LT recipients with confirmed SARS-CoV-2-infection. Data were collected at diagnosis of COVID-19 and during follow-up and compared with the regional population. Thirty LT recipients (3.28%) developed SARS-CoV-2-infection (76.66% male, median age 62.61 years). Sixteen (53.33%) were symptomatic. Common symptoms were fever, cough, fatigue, and anosmia. Twenty-five (83.33%) were outpatients, 5 (16.66%) required hospitalization (6.66% admitted to Intensive Care Unit, 6.62% developed Acute Respiratory Distress Syndrome and 6.66% died). Immunosuppressors were in 3 (10%) patients. Incidence rate of COVID-19 was similar between LT patients and general population (3.28% vs 4.37%, p = 0.142) with higher rate of symptoms in LT patients (53.33% vs 15.87%, p
- Published
- 2021